Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [¹⁸F]-Flutemetamol PET Scan Result.

ABSTRACT: Background: Blood biomarkers may aid in recruitment to clinical trials of Alzheimer's disease (AD) modifying therapeutics by triaging potential trials participants for amyloid positron emission tomography (PET) or cerebrospinal fluid (CSF) Aβ and tau tests. Objective: To discover a plasma proteomic signature associated with CSF and PET measures of AD pathology. Methods: Liquid chromatography-tandem mass spectrometry (LC-MS/MS) based proteomics were performed in plasma from participants with subjective cognitive decline (SCD), mild cognitive impairment (MCI), and AD, recruited to the Amsterdam Dementia Cohort, stratified by CSF Tau/Aβ₄₂ (n = 50). Technical replication and independent validation were performed by immunoassay in plasma from SCD, MCI, and

SUBMITTER: Westwood S 

PROVIDER: S-EPMC6297196 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature